Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLCP-004-1
- Development stage
- Preclinical
- Lead developer
- Galenica
- Modality
- Small Molecules
01
Overview
GLCP-004-1 is a small molecule drug candidate currently in development by Galenicap for the treatment of treatment-resistant schizophrenia (TRS). TRS is a severe form of schizophrenia where patients do not respond adequately to at least two different antipsychotic treatments, representing a significant area of unmet medical need. While Galenicap has identified GLCP-004-1 as a key asset in its CNS portfolio, specific details regarding its molecular target, pharmacological profile, and current clinical phase have not been publicly disclosed. The program aims to provide a novel therapeutic option for patients who are refractory to existing antipsychotic medications.
Beyond the preview
Go deeper on GLCP-004-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLCP-004-1.